Table S1.
Breakdown of responses to the Patient Satisfaction with Medication Questionnaire–Modified by galcanezumab dose group and visit
| Galcanezumab 120 mg, n (%) | Galcanezumab 240 mg, n (%) | |||||
|---|---|---|---|---|---|---|
| Month 1 (N=131) | Month 6 (N=117) | Month 12 (N=90) | Month 1 (N=133) | Month 6 (N=121) | Month 12 (N=112) | |
| Satisfaction | ||||||
| Very dissatisfied | 13 (9.92) | 21 (17.95) | 15 (16.67) | 12 (9.02) | 26 (21.49) | 20 (17.86) |
| Somewhat dissatisfied | 5 (3.82) | 5 (4.27) | 2 (2.22) | 2 (1.50) | 4 (3.31) | 4 (3.57) |
| Neutral | 27 (20.61) | 13 (11.11) | 4 (4.44) | 20 (15.04) | 5 (4.13) | 6 (5.36) |
| Somewhat satisfied | 44 (33.59) | 25 (21.37) | 17 (18.89) | 40 (30.08) | 27 (22.31) | 17 (15.18) |
| Very satisfied | 42 (32.06) | 53 (45.30) | 52 (57.78) | 59 (44.36) | 59 (48.76) | 65 (58.04) |
| Preference | ||||||
| Much prefer previous | 1 (0.76) | 4 (3.42) | 0 (0.00) | 1 (0.75) | 4 (3.31) | 4 (3.57) |
| Prefer previous | 9 (6.87) | 5 (4.27) | 3 (3.33) | 6 (4.51) | 5 (4.13) | 5 (4.46) |
| Neutral | 25 (19.08) | 10 (8.55) | 7 (7.78) | 28 (21.05) | 7 (5.79) | 12 (10.71) |
| Prefer study medication | 52 (39.69) | 42 (35.90) | 20 (22.22) | 51 (38.35) | 35 (28.93) | 20 (17.86) |
| Much prefer study medication | 44 (33.59) | 56 (47.86) | 60 (66.67) | 47 (35.34) | 70 (57.85) | 71 (63.39) |
| Side effects | ||||||
| Much less side effects | 55 (41.98) | 54 (46.15) | 60 (66.67) | 56 (42.11) | 73 (60.33) | 57 (50.89) |
| Less side effects | 38 (29.01) | 30 (25.64) | 13 (14.44) | 39 (29.32) | 25 (20.66) | 34 (30.36) |
| The same as previous | 31 (23.66) | 20 (17.09) | 13 (14.44) | 28 (21.05) | 17 (14.05) | 16 (14.29) |
| More side effects | 0 (0.00) | 1 (0.85) | 0 (0.00) | 1 (0.75) | 1 (0.83) | 0 (0.00) |
| Much more side effects | 7 (5.34) | 12 (10.26) | 4 (4.44) | 9 (6.77) | 5 (4.13) | 5 (4.46) |